---
title: "002107.SZ (002107.SZ) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/002107.SZ/news.md"
symbol: "002107.SZ"
name: "002107.SZ"
parent: "https://longbridge.com/zh-HK/quote/002107.SZ.md"
datetime: "2026-03-10T16:02:43.526Z"
locales:
  - [en](https://longbridge.com/en/quote/002107.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002107.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002107.SZ/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/002107.SZ/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/002107.SZ/news.md)


# 002107.SZ (002107.SZ) — 相關新聞

### [WHYY: How to Win a Tough Battle That Concerns the Future](https://longbridge.com/zh-HK/news/274767724.md)
*2026-02-04T06:35:57.000Z*
> WHYY reported an operating income of 817 million yuan in its 2025 annual report, a year-on-year increase of 6.96%, and a

### [WHYY's "Environmental Protection Window" Reveals the Dilemma of ESG Disclosure](https://longbridge.com/zh-HK/news/274644096.md)
*2026-02-03T11:05:06.000Z*
> Shandong WHYY failed to adequately disclose environmental and climate information in its 2025 annual report, reflecting 

### [WHYY: "In-hospital + Out-of-hospital" transformation breakthrough dual-engine drive for rapid growth](https://longbridge.com/zh-HK/news/274411548.md)
*2026-02-01T07:42:08.000Z*
> Against the backdrop of deepening policy adjustments in the pharmaceutical industry and overall pressure on the traditio

### [Behind WHYY's impressive annual report: 50% of revenue used for sales, continuously funding loss-making subsidiaries | Dayu Finance](https://longbridge.com/zh-HK/news/274159373.md)
*2026-01-29T13:26:12.000Z*
> Shandong WHYY Pharmaceutical Technology Co., Ltd. released its 2025 annual report, with operating revenue of 817 million

### [Healthcare Industry Daily (01.20): Breakthroughs in Biopharmaceutical Innovation](https://longbridge.com/zh-HK/news/273124135.md)
*2026-01-20T19:21:44.000Z*
> AMOYTOP has made significant progress in the fields of liver disease and children's growth, with operating revenue expec

### [The first A-share annual report for 2025 is out: WHYY earned a net profit of over 95 million yuan last year, and the company has entered a state of no actual controller](https://longbridge.com/zh-HK/news/273392482.md)
*2026-01-20T02:18:15.000Z*
> WHYY (SZ002107) released its 2025 annual report on January 19, 2026, with annual revenue of 817 million yuan, a year-on-

### [Overview of A-share dividends and stock distributions: 2 stocks have their equity registration today](https://longbridge.com/zh-HK/news/273007220.md)
*2026-01-19T23:46:46.000Z*
> According to Wind data, based on the equity distribution plans of listed companies, 2 A-shares will have their equity re

### [WHYY released its 2025 annual performance, with a net profit attributable to the parent company of 95.7153 million yuan, an increase of 162.93%](https://longbridge.com/zh-HK/news/272984156.md)
*2026-01-19T14:45:03.000Z*
> WHYY released its annual report for 2025, with operating revenue of 817 million yuan, a year-on-year increase of 6.96%. 

### [The first annual report of A-shares is out! 002107, performance surged!](https://longbridge.com/zh-HK/news/272984228.md)
*2026-01-19T14:45:02.000Z*
> On the evening of January 19th, WHYY was the first to disclose its annual report for 2025, becoming the first listed com